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The leukocyte specific protein 1 or LSP1 is a multi functional protein involved in such divers biological processes as the regulation of
neutrophil motility, chemotaxis, adhesion and membrane immunoglobulin M (mIgM) mediated apoptosis of B-lymphocytes. The 330-amino-
acid mouse LSP1 protein contains a high-affinity F-actin binding site and in intact cells localizes to the F-actin filament containing
cytoskeleton. Here we use a high-speed F-actin co sedimentation assay and transfection experiments in the LSP1 T-lymphoma cell line
BW5147 to show that LSP1 interacts with F-actin and the cytoskeleton through residues downstream of amino acid residue 230. We then
designed a novel cell-free cytoskeleton binding assay in which a set of GST–LSP1 fusion proteins are allowed to bind to the cytoskeleton in
NP-40 soluble lysates of BW5147 cells and are recovered in the low-speed detergent insoluble pellet. Using this assay the cytoskeleton
binding site of mouse LSP1 maps to the 300–330 interval. These results will allow the design of LSP1 mutants that do not bind to the
cytoskeleton to determine the importance of LSP1 cytoskeleton binding for the diverse functions of LSP1.D 2003 Elsevier B.V. All rights reserved.Keywords: Leukocyte specific protein 1; Cytoskeleton; F-actin; Cell-free cytoskeleton binding assay; Adhesion; Motility; Apoptosis1. Introduction
The cytoskeletal protein leukocyte specific protein 1
(LSP1) is involved in the regulation of neutrophil motility
in vitro and in vivo and in the regulation of neutrophil
adhesion to the matrix protein fibrinogen [1–4]. LSP1 is
expressed in lymphocytes, neutrophils and macrophages but
not in other hematopoietic or non-hematopoietic cells [5–
8]. Mouse LSP1 protein contains 330 amino acids and
shares significant sequence homology with the 339 amino
acid human LSP1 protein, also known as WP34 or pp52 [9–
11]. Mouse and human LSP1 bind to F-actin in vitro and to
F-actin filaments in intact cells [4,9,12,13]. Mouse LSP1
binds to F-actin and to the cytoskeleton through its COOH-
terminal residues 179–330 [9]. The COOH-terminal resi-
dues 180–339 of human LSP1 contain several F-actin0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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homology to sequences found in the F-actin binding protein
caldesmon and two designated VI and VII with homology to
villin [12]. Each of the four F-actin binding domains in
human LSP1 contributes to F-actin binding in vitro and,
when expressed in Sf9 insect cells, all F-actin binding
domains need to be present for LSP1 to function as an F-
actin bundling protein in intact cells [12,14]. Since the
bundling activity of human LSP1 depends on the presence
of multiple F-actin binding sites, the above experiments did
not directly address which sequences in LSP1 are sufficient
for binding to F-actin filaments. To address this question,
we mapped the F-actin and cytoskeletal binding site of
mouse LSP1 using several approaches. First, using truncat-
ed LSP1 proteins in an in vitro high-speed co-sedimentation
assay or expressed in vivo in the LSP1 T-lymphoma cell
line BW5147, we showed that the F-actin binding site and
the cytoskeletal binding site of mouse LSP1 are located
downstream of LSP1 residue 230. We then designed an in
vitro cell-free cytoskeleton binding assay and determined
that the cytoskeleton binding site of LSP1 is located
between residues 300 and 330. These residues contain the
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VII domains. The mouse sequences homologous to regions
CI and CII in human LSP1 do not contribute to F-actin
binding or to cytoskeletal binding of mouse LSP1.2. Materials and methods
2.1. Cells and media
The LSP1 T-lymphoma cell line BW5147 was grown in
complete RPMI-1640 tissue culture medium supplemented
with 10% FCS as described [9].
2.2. Antisera and Western blot analysis
Western blot analysis was performed on Immobilon
membranes (Millipore Corp., Bedford, MA). Proteins were
analyzed with anti-LSP1 serum [15], anti-actin monoclonal
antibodies [9] or an anti-serum that recognizes glutathione-
S-transferase (GST) and visualized using the ECL detection
kit (Amersham BioSciences, Oakville, Ontario).
2.3. Construction of recombinant LSP1 mutant proteins
Eukaryotic expression vectors encoding LSP1-CAT fu-
sion proteins containing LSP1 residues 1–330, 1–178, 1–
230, 1–178/231–330 or 179–330 of LSP1 were con-
structed as described in Ref. [9]. Constructs were then
stably transfected into BW5147 cells by electroporation
(450 V, 150 AF) using the BioRad electroporator system.
The GST–LSP1 fusion proteins containing residues 1–300,
1–178, 179–330, 179–230, 231–330, 270–330, 285–330,
300–330 and 231–300 were constructed using PCR with
the mouse LSP1 cDNA as template. The DNA fragments
were subcloned into the pBluescript II KS (+) vector
(Stratagene, La Jolla, CA) for sequencing and then trans-
ferred into the pGEX-4T-2 vector (Amersham Biosciences).
All DNA fragments were expressed as GST–LSP1 fusion
proteins in E. coli BL21(DE3) cells. Recombinant proteins
were purified according to standard procedures and the
concentration of each recombinant protein was calculated
by using the optical density measurement at 280 and 320
nm, the extinction coefficients of tyrosine (1390 M 1
cm 1) and tryptophan (5800 M 1 cm 1) and the number
of tyrosine and tryptophan residues present in each GST–
LSP1 fusion protein.
2.4. In vitro F-actin binding assay and Scatchard analyses
The high-speed co-sedimentation F-actin binding assay
was performed exactly as described previously using 5 Ag of
GST or GST–LSP1 fusion proteins and 4 AM rabbit skeletal
muscle actin in a total volume of 100 Al [9]. To control for
the solubility of the GST–LSP1 proteins, the assays were
also done without added actin. The amount of GST orGST–LSP1 fusion protein in the high-speed pellet was
determined as a fraction of the amount of input protein by
densitometry using a standard curve constructed of a series
of twofold dilutions of the input protein as described [9].
For Scatchard analyses, a constant amount of actin was
mixed with varying amounts of GST fusion protein and
polymerized. The amount of polymerized actin in the pellet
was independent of the amount of added GST fusion protein
and was between 0.8 and 1.0 Amol.
2.5. In vivo cytoskeletal binding assay
BW5147 cells and stable transfectants expressing LSP1–
CAT fusion proteins were lysed by incubation with deter-
gent and the detergent insoluble cytoskeletal material was
purified through a sucrose cushion as described [9,16]. At
least three independent assays were done for each BW5147
transfectant and the results are presented as the average
extent of cytoskeletal binding F 1 S.D.
2.6. Preparation of a nuclear fraction by nitrogen cavitation
Cells (5 107) of the BW5147 transfectant BW20 were
washed three times in cold PBS. Cells were resuspended in
lysis buffer without NP-40 at a concentration of 1107
cells/ml and disrupted using a Parr Cell Disruption Bomb
#4639 filled with N2 gas at a pressure of 700 psi. The entire
crude lysate (5 ml) was layered on 2 ml of a 0.88M sucrose
cushion and centrifuged at 1300 g for 8 min. Lysis buffer
containing 0.5% NP-40 was added to the pellet and centri-
fuged as above. The resulting nuclear fraction was resus-
pended in Laemmli sample buffer and immersed in boiling
water for 5 min. In parallel, cells were also lysed with NP-
40 and centrifuged as above to generate a NP-40 insoluble
pellet. A total cell lysate was generated by lysis of cells in
SDS-containing sample buffer. All samples were immersed
in boiling water for 3 min after the addition of Laemmli
sample buffer. To check for histone content, aliquots of the
NP-40 insoluble pellet and the nuclear fractions were
separated on a SDS-12.5% polyacrylamide gel and stained
with Coomassie brilliant blue.
2.7. Cell-free cytoskeletal binding assay
BW5147 cells were lysed as described for the in vivo
cytoskeleton binding assay at a cell density of 4 107 cells/
ml. GST–LSP1 fusion proteins (15 Al containing f 5 g of
protein diluted in 50% glycerol) were added to 100 Al of
BW5147 lysate and incubated on ice for 45 min. Next, two
aliquots of 50 Al were collected. One aliquot was designated
as the input sample and was used to prepare a calibration
curve for quantitation purposes. The other aliquot was
centrifuged at 14,000 g in a microfuge (Biofuge A,
American Scientific Products) for 5 min at 4 jC to pellet
the detergent-insoluble cytoskeleton. The cytoskeletal pellet
was washed once with lysis buffer and then dissolved in 75
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for 5 min. Proteins in the pellet fractions and those from the
input sample were separated on SDS-12.5% PAGE and the
amount of each GST–LSP1 fusion protein present in the
pellet fraction was quantitated by Western blot analysis as
the percentage of input GST–LSP1 fusion protein. To
quantitate cytoskeletal binding, a calibration curve was used
that was constructed by analyzing twofold dilutions of input
protein. At least three independent assays were done for
each GST–LSP1 fusion protein and the results are presented
as the average percent of cytoskeletal binding F 1 S.D.Fig. 1. LSP1 residues 231–330 bind to F-actin in vitro. (A) The binding of GST a
high-speed co-sedimentation assay. Results are presented as the average perce
Representative examples of the co-sedimentation assays for GST, GST–LSP1/179
high-speed pellets and the corresponding supernatants were analyzed by SDS-PA
supernatants from assays in the presence or absence of actin. Lanes 2 and 4 are the
actin or GST and GST–LSP1 fusion proteins are indicated with filled or open ar
231–330 to F-actin. Two curves were fitted by linear regression analysis indicatin
binding of GST–LSP1/231–330 to F-actin.3. Results
3.1. Residues 231–330 of LSP1 are sufficient for F-actin
and cytoskeleton binding
Using a high-speed F-actin co-sedimentation assay, we
have shown that LSP1 binds to F-actin through residues
179–330, while residues 1–178 do not bind to F-actin [9].
Experiments shown in Fig. 1A confirm these results in a
quantitative manner. At approximately equal molar input,
similar fractions of intact LSP1 residues 1–330 (39.1%) ornd the indicated GST–LSP1 fusion proteins to F-actin was determined in a
nt of binding F 1 S.D. calculated from at least three experiments. (B)
–230, GST–LSP1/231–330 and GST–LSP1/1–330. Equal fractions of the
GE followed by Coomassie blue staining. Lanes 1 and 3 in each panel are
high-speed pellets from assays with or without added actin. The positions of
rows respectively. (C) Quantitative analysis of the binding of GST–LSP1/
g the presence of high- and low-affinity binding. The inset shows saturable
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fraction of GST–LSP1/1–178 in the high-speed pellet
(2.6%) was not significantly different from the amount of
GST protein (0.9%). To more precisely determine the LSP1
sequences involved in F-actin binding, we tested GST–
LSP1 fusion proteins containing different intervals of the
179–330 sequence. Fig. 1A shows that 30.3% of GST–
LSP1/231–330 binds to F-actin, while only 0.4% of GST–
LSP1/179–230 binds to F-actin. The presence of GST–
LSP1/231–330 in the high speed pellet was not due to
insolubility of the GST–LSP1 fusion protein in the assay
buffer as no recombinant LSP1 protein was detectable in the
high-speed pellet when actin was omitted from the binding
assay (Fig. 1B third panel, lane 4). Binding of LSP1
residues 231–330 was not significantly different from the
binding of either intact LSP1 residues 1–330 or of residues
179–330. Examples of binding assays for GST–LSP1/1–
330, GST–LSP1/231–330 and GST–LSP1/179–230 are
shown in panel B. Binding of GST–LSP1/231–330 to F-
actin was saturable at a molar ratio of approximately 1:1
(Fig. 1C, inset). Scatchard analysis showed that the disso-
ciation constant for binding of GST–LSP1/231–330 to F-
actin is f 0.2 AM with an apparent stoichiometry of
binding of f 0.5 mol of GST–LSP1/231–330 per mole
of F-actin. These values are very similar to those found for
the dissociation constant (0.2 AM) and stoichiometry of
binding (0.6) when intact LSP1 was used for binding [9].
Thus, we conclude from these results that the main F-actin
binding site of mouse LSP1 is located downstream of
residue 230 in the 231–330 interval. Similar to the findings
for intact LSP1, we also found low-affinity binding of
GST–LSP1/231–330. However, this may reflect nonspe-
cific binding of the fusion protein to F-actin filaments or
trapping of small amounts of the fusion protein in the F-
actin filament pellet.
The presence of an F-actin binding domain between
LSP1 residues 231 and 330 predicts that these residues are
sufficient to direct LSP1 to the F-actin filaments when
expressed in cells. To confirm this prediction, we expressed
intact LSP1 (residues 1–330) and a mutated form of LSP1
from which residues 179–230 have been deleted (1–
330D179–230) in the LSP1 T-lymphoma cell line
BW5147 cells. To ensure stable expression of LSP1 truncate
we fused the LSP1 sequences to the NH2 terminus of the
bacterial CAT protein. All constructs were expressed at
similar levels (A.I. Malapitan and J. Jongstra, unpublished
data). Cytoskeletal binding was determined using anti-CAT
antibodies to assay the amount of LSP1–CAT fusion protein
in the NP-40 insoluble pellet of BW5147 cells stably
expressing the LSP1–CAT fusion proteins. Fig. 2A shows
that 30.5% of the CAT–LSP1/1–330 fusion protein was
present in the cytoskeletal pellet of BW4 cells, while a
similar fraction of the LSP1–CAT/1–330D179–230
(27.4%) was present in the cytoskeletal pellet of BW20
cells. Fig. 2B shows a representative Western blot used
to quantitate the cytoskeleton binding of GST–LSP1/1–330D179–230 protein expressed in the transfectant
BW20. The NP-40 insoluble cytoskeletal pellet fraction
from 2 105 BW20 cells contains approximately as much
protein as the total lysate from 0.5 105 BW20 cells
(compare lanes 1 and 3), indicating that in this particular
experiment f 25% of the expressed CAT–LSP1/1–
330D179–230 protein binds to the cytoskeleton. The pres-
ence of the LSP1–CAT/1–330D179–230 protein in the
cytoskeletal pellet of BW20 cells was not due to the
presence of LSP1 residues 1–178 or of the CAT protein
since only a small fraction of these sequences was present in
the cytoskeletal pellets of BW57 and BW711 cells, respec-
tively (Fig. 2A). Cytoskeleton binding of the LSP1 se-
quence 179–230 that are deleted from CAT–LSP1/1–
330D179–230 was not significantly higher than that of
residues 1–178. Thus these results show that LSP1 residues
231–330 direct the binding of LSP1 to the NP-40 insoluble
cytoskeletal pellet.
Since the NP-40 insoluble pellet contains the nucleus as
well as F-actin filaments [17], we needed to confirm that the
CAT–LSP1/1–330D179–230 protein expressed in the
transfected line BW20 is present in the NP-40 detergent
insoluble fraction because of an association with the cyto-
skeleton and not because it is associated with the nucleus or
is merely insoluble in the lysis buffer used. To address this,
we made nuclear fractions of BW20 cells using nitrogen
cavitation under conditions which disrupt the cytoskeleton
but leaves the nuclear fraction intact. The yield of the
nuclear fraction as determined by analyzing the histone
content on Coomassie blue-stained SDS-PAGE was essen-
tially 50% as the nuclear fraction of 8 105 BW20 cells
(panel C, lane 2) contains an amount of histones approxi-
mately equal to 4 105 cell equivalents of the NP-40
insoluble pellet (lane 1) or of a total lysate (not shown).
Lysis using nitrogen cavitation results in extensive disrup-
tion of the cytoskeleton as measured by the absence of actin
in the nuclear pellet, which contains less than 1/8th the
amount of actin present in the NP-40 insoluble pellet (panel
D, lanes 2 and 3). Importantly, the amount of CAT–LSP1/
1–330D179–230 protein in the nuclear fraction is reduced
to a similar extent (panel B, lanes 4 and 5). Thus, the LSP1/
1–330D179–230 protein containing the F-actin binding
domain within residues 231–330 is present in the detergent
insoluble fraction of BW20 cells due to its association with
the cytoskeleton and not with the nucleus or as a result of
insolubility in the lysis buffer used.
3.2. Residues 300–330 of LSP1 are sufficient for
cytoskeletal binding in a cell-free cytoskeletal binding assay
To further map the cytoskeletal binding site of LSP1
between residues 231 and 330, we decided to use a cell-free
binding assay to analyze a set of GST–LSP1 fusion proteins
instead of using transfected BW5147 cells. The results of
multiple binding assays are tabulated in Fig. 3A and
representative examples are shown in panels B–D. For
Fig. 2. LSP1 residues 231–330 bind to the cytoskeleton. (A) The indicated LSP1–CAT fusion proteins were expressed in the LSP1 T-lymphoma cell line
BW5147. The average amount F 1 S.D. of each expressed fusion protein present in the NP-40 insoluble pellet is calculated from at least three experiments.
The name of each stable transfected cell line is indicated at the right. (B) Western blot analysis of a typical experiment to quantitate the amount of the CAT–
LSP1/1–330D178–230 protein in the NP-40 insoluble cytoskeletal pellet (lanes 3 and 4) or in the nuclear pellet (lanes 5 and 6) compared to the total amount
of CAT–LSP1/1–330D178–230 protein (lanes 1 and 2) present in the BW20 transfectant. (C) The amount of histones in the NP-40 insoluble and nuclear
pellets was visualized after SDS-PAGE by Coomassie blue staining. (D) Western blot analysis of actin in NP-40 insoluble and nuclear pellets. The positions of
molecular weight markers are indicated in Kd at the left of each panel.
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to quantitate the extent of cytoskeletal binding of GST–
LSP1/1–330 in the cell-free binding assay. LSP1neg
BW5147 T-lymphoma cells (4 106) were lysed using
0.5% NP-40 and incubated with 5 Ag of the GST–LSP1/
1–330 on ice for 45 min to allow binding of the GST–LSP1
protein to the cytoskeleton present in the BW5147 NP40
lysate. After centrifugation for 5 min at 14,000 rpm, the
amount of GST–LSP1/1–330 protein present in the NP-40
insoluble cytoskeletal pellet was determined by densitome-
try. Fig. 3B shows that in this particular experiment 23.5%
of the input GST–LSP1/1–330 fusion protein bound to the
cytoskeleton (Pel). The GST–LSP1/1–330 protein is not
insoluble in lysis buffer containing 0.5% NP-40 since no
fusion protein was detected in the pellet fractions from
binding assays in which the fusion protein was incubated
in lysis buffer containing 0.5% NP-40 without BW5147
lysate (Cntrl). No cross-reacting band was present in the
BW5147 lysate at the same level as the GST–LSP1/1–330
fusion protein, as determined by analyzing the BW5147
lysate without addition of GST–LSP1/1–330 protein (Lys).No significant proteolysis of the fusion protein occurs
during the assay as determined by comparing the non-bound
(Sup) with the input GST–LSP1/1–330 fusion protein.
Panel A shows that 24.9% of the GST–LSP1/1–330 protein
(line 1), 31.0% of GST–LSP1/179–330 (line 3) and 28.6%
of the GST–LSP1/231–330 protein (line 5) bind to the
cytoskeleton in BW5147 cell lysates, while < 0.25% of the
GST–LSP1/1–178 (line 2) and < 0.5% of the GST–LSP1/
179–230 protein (line 4) bind to the cytoskeleton. These
results show that the cytoskeleton binding site is located
between residues 231 and 330 and that the use of the cell-
free binding assay or analysis of stable transfectants leads to
the same conclusion.
We assayed six additional GST–LSP1 proteins. Signif-
icant binding to the cytoskeleton was detected for proteins
containing LSP1 residues 270–330 (24.7%), 285–330
(29.0%) and 300–330 (21.2%, lines 6–8), but not for the
GST–LSP1/1–300 ( < 1%) and the GST–LSP1/231–300
( < 0.5%, lines 9 and 11) proteins. This is strong evidence
that only residues in the 300–330 interval contribute to
cytoskeletal binding. Analysis of the cytoskeletal binding
Fig. 3. Cytoskeletal binding of GST–LSP1 fusion proteins in a cell-free
assay. (A) The indicated GST–LSP1 fusion proteins were tested for
cytoskeletal binding using a cell-free cytoskeletal binding assay. Results are
presented as the average binding F 1 S.D. from at least three experiments.
(B) shows a representative example of the quantitation of cytoskeletal
binding of the GST–LSP1/1–330 protein. The amount of GST–LSP1/1–
330 protein in the cytoskeletal pellet (Pel) is quantitated by densitometry
using a standard curve constructed from a series of twofold dilutions of the
input protein. No protein from the lysate is present in the pellet when the
fusion protein is omitted (Lys) or when the fusion protein is assayed in the
absence of lysate (Cntrl). No significant protein degradation is detectable in
the unbound fusion protein (Sup) when compared to the input protein. (C)
and (D) are examples of binding assay using GST–LSP1/300–330 or
GST–LSP1/1–300. The Western blots were probed with an anti-serum that
recognizes GST.
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330 and 300–330 of LSP1 by ANOVA showed that the
slight variations in the extent of cytoskeletal binding were
not significant (P>0.05). Thus, we conclude that the cyto-
skeletal binding site of LSP1 is located between residues
300 and 330.4. Discussion
Several studies have shown that LSP1 is involved in the
regulation of cell motility, adhesion to extracellular matrix
proteins and cell morphology. Howard et al. [3,4] showed
that overexpression of LSP1 in human neutrophils or in
human melanoma cells inhibits cell motility and leads to the
formation of LSP1 and F-actin containing membrane pro-
trusions. Our lab has shown that compared to neutrophils
from wild-type mice, neutrophils from Lsp1 / mice dis-
play increased chemotaxis towards a gradient of the chemo-
attractant KC and fMLP and show increased adhesion to
fibrinogen but not to fibronectin [1,2]. The F-actin and
cytoskeletal binding characteristics of LSP are consistent
with its role as a regulator of cell motility and adhesion as
these are cytoskeleton-dependent biological processes. On
the other hand, expression of the COOH-terminal LSP1
residues 179–330 in the mouse B-lymphoma cell line W10
results in the inhibition of anti-immunoglobulin M (IgM)-
induced activation of the PKC/ERK MAPkinase pathway
and increases anti-IgM-induced apoptosis, which shows that
LSP1 is a regulator of membrane IgM (mIgM)-induced
apoptosis and that the residues critical to this apoptotic
function of LSP1 reside between residues 179 and 330. In
addition to binding F-actin and the cytoskeleton, LSP1
residues 179–330 also bind directly to PKChI [18]. This
suggests that LSP1 targets at least a fraction of the intra-
cellular PKChI and possibly other components of the PKC/
ERK MAPkinase pathway to a cytoskeletal location. Al-
though cytoskeletal proteins such as Hsp25/27 [19], gelsolin
[20,21] or DAP kinase [22] have been shown to be involved
in the regulation of apoptosis, it needs to be determined
whether cytoskeletal binding of LSP1 and targeting PKChI
to the cytoskeleton is important for its function as a
regulator of anti-IgM induced apoptosis. Using expression
of LSP1 truncates or mutants that do not bind to the
cytoskeleton in W10 cells may clarify this point.
The objective of the studies in this paper was to define
the sequences sufficient for mouse LSP1 to bind the
cytoskeleton. Previous experiments showed that mouse
LSP1 binds to F-actin and to the cytoskeleton through the
COOH-terminal residues 179–330 [9]. A more detailed
study on human LSP1 identified at least three and possibly
four specific regions in the COOH-terminal half of human
LSP1 that each individually can function as an F-actin
binding site [12], suggesting that binding of LSP1 to the
F-actin filaments in intact cells involves three or four
binding sites. Indeed, it was shown that all F-actin binding
sites were necessary for human LSP1 to function as an F-
actin bundling protein [14]. However, the question of which
of these F-actin binding sites in human LSP1 are sufficient
for cytoskeletal binding was not addressed. Here we de-
scribe a novel cell-free cytoskeletal binding assay and use
this assay to map the cytoskeletal binding site of LSP1
between residues 300 and 330. We quantitated the cytoskel-
etal binding activity of the recombinant LSP1 protein frag-
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by measuring the amount of intact or truncated LSP1 protein
in the NP-40 insoluble pellet fraction. We now have
performed two appropriate control experiments that show
that the intact endogenous LSP1 protein expressed in the B-
lymphoma cell line BAL-17 [16] or the fusion protein
containing LSP1 residues 1–178/231–330 expressed in
the transfectant BW20 (this paper) are present in the NP-
40 insoluble pellet because of an association with insoluble
cytoskeletal elements and not because of a nuclear location
or because of insolubility in the lysis buffer. Thus we
conclude that the data in Fig. 2 represent the extent of
cytoskeletal binding of the various LSP1 fusion proteins
assayed, rather than their binding to the nucleus. We tested
the validity of the cell-free binding assay by comparing the
results obtained in that assay with those using the in vivo
expressed proteins. Using intact LSP1 and four LSP1 frag-
ments (1–178, 179–230, 179–330 and 231–330), both
methods mapped the cytoskeleton binding site to the same
region downstream of LSP1 residue 230, which suggests
strongly that the results obtained using the cell-free assay
are valid measurements of cytoskeleton binding. The cell-
free assay is, however, much less time-consuming as it is not
necessary to establish stable transfectants for each mutated
LSP1 protein assayed and therefore should permit the use of
a larger collection of LSP1 mutants leading to a more
accurate mapping of the LSP1 cytoskeletal binding
domains. Indeed, we used an additional six LSP1 truncates
to map the cytoskeleton binding site to the LSP1 residues
300–330.
Our results using mouse LSP1 differ from those de-
scribed for human LSP1 [12,14]. The only F-actin and
cytoskeletal binding sites in mouse LSP1 are present down-
stream of residue 300, while the results of mapping experi-
ments using human LSP1 would predict the presence of two
F-actin binding domains in mouse LSP1 upstream of residue
300, between residues 196–228 (homologous to the human
CI domain) and residues 251–267 (homologous to the
human CII domain). However, it is unlikely that the mouse
sequence 196–228 contributes to F-actin binding of LSP1
in vitro since the sequence 179–230 does not bind to F-
actin as shown in Fig. 1. Scatchard analyses of the binding
data (Fig. 1C) also support the conclusion that the main F-
actin binding activity is located in the 231–330 region. We
have previously calculated the Kd of binding of rLSP1 to F-
actin as approximately 0.2 AM and Scatchard analysis of the
binding data of the GST–LSP1/231–330 is in good agree-
ment with the measurements using intact LSP1, both giving
a Kd of approximately 0.2 AM and a final stoichiometry of
binding of approximately 0.6 mol of LSP1 for each mole of
actin. Thus there is good evidence that LSP1 interacts with
F-actin only through sequences downstream of residue 231.
Similarly, we have no evidence that either residues 196–228
or residues 251–267 of mouse LSP1 contribute to the
cytoskeletal binding of LSP1, since neither GST–LSP1/
179–230 nor GST–LSP1/231–300 bind to the cytoskeleton(Figs. 2 and 3). The reason why we were not able to
demonstrate the presence of functional CI and CII domains
in mouse LSP1 is not clear, but does not seem to be related
to differences in binding assays or source of recombinant
protein. Both mouse and human CI domain-containing
truncates were assayed for F-actin binding using the high-
speed co-precipitation assay using bacterially derived re-
combinant proteins [12]. Comparison of the mouse and
human sequences of the CI and CII domains, however,
showed six differences between mouse and human CI
domains and four differences between human and mouse
CII domains. Hence, the mouse CI and CII domains may not
be functional because of differences in residues critical for
F-actin binding. In agreement with the results obtained with
human LSP1, we found that mouse LSP1 residues 300–330
bind to F-actin. These residues contain the sequences 307–
310 and 318–321 that are identical to the human VI and VII
sequences, respectively. The VI and VII sequences are short
basic sequence motifs (KRYK and KYEK, respectively) that
resemble an F-actin binding motif (KKEK) in the headpiece
of villin. Mutation of one or two basic residues in VI or VII
significantly inhibited binding of human LSP1 for F-actin,
indicating that the VI and VII motifs contribute indepen-
dently to the F-actin binding characteristics of human LSP1
[12]. We have not made single or double point mutations in
the mouse VI or VII sequences and thus our results do not
allow us to conclude whether these specific sequences are
involved in F-actin and cytoskeletal binding. However, we
showed that only 1.9% of a GST fusion protein containing
LSP1 residues 231–320 that eliminates the C-terminal K
residue of the VII domain binds to the cytoskeleton in the
cell-free assay (Fig. 3A, line 10), suggesting that in agree-
ment with the mutation studies of Howard et al., changes in
the basic residues of the VII domain significantly inhibit the
F-actin binding characteristics of LSP1.Acknowledgements
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